AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04851795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised physical exercise sessions
Description: Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
Study NCT04851795 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: unsupervised physical exercise
Description: For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
Study NCT06002386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vsling
Description: Implantable ventricular repair device
Study NCT06754475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-volume, high-intensity interval training
Description: Low-volume, high-intensity interval training with an arm ergometer will be given two days a week for a total of eight weeks.
Study NCT06754475 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standart medical treatment
Description: Standart medical teatment
Study NCT06756867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand massage with violet oil
Description: In this study, individuals receiving hemodialysis treatment will be massaged with 2% violet oil for 5-7 minutes on the hand on the non-fistula arm during the dialysis session, 3 times a week for six weeks.
Study NCT06756867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hand massage with jojoba oil
Description: Hand massage with jojoba oil for hemodialysis patients 3 times a week for 6 weeks
Study NCT06756971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered until the patients is in an optimal plane that mimics natural sleep while spontaneously breathing to allow for a DISE evaluation
Study NCT06756971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be administered until the patients is in an optimal plane that mimics natural sleep while spontaneously breathing to allow for a DISE evaluation
Study NCT06757387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide and golidocitinib
Description: Enrolled patients will receive combination therapy with golidocitinib (150 mg QD or 150 mg QOD) and chidamide (20 mg BIW or 25 mg BIW)； If the MTD is determined at Dose Level 1 (chidamide 20 mg BIW / golidocitinib 150 mg QD), Dose Level 0 (chidamide 20 mg BIW / golidocitinib 150 mg QOD) will be further investigated. If the MTD is not established after escalating to Dose Level 2 (chidamide 25 mg BIW / golidocitinib 150 mg QD), the recommended Phase 2 dose (RP2D) will be determined through investigator consensus.
Study NCT06496568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.
Study NCT06496568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab, 1200 mg, as IV infusion Q3W on Day 1 of each 21-day cycle.
Study NCT06113640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa-carbidopa
Description: Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
Study NCT06344156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
Description: Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines
Study NCT05011526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study NCT05011526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study NCT05314959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Awareness
Description: The patients' pre-visit Control Preference Scale responses are shared with their physician.
Study NCT05314959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The patients' pre-visit Control Preference Scale responses are not shared with their physician.
Study NCT06393881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI059
Description: take UI059 once a day for 7 days
Study NCT06393881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UIC202201
Description: take UIC202201 once a day for 7 days
Study NCT04900285 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delta Dental Oral Device
Description: The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described.
Study NCT05733078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
Study NCT05733078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Rehydration Salt Formulations
Description: The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
Study NCT05814809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg tablet
Description: T : JP-1366 20mg tablet
Study NCT05814809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg capsule
Description: R : JP-1366 20mg capsule
Study NCT05963971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEDALL
Description: twenty-six hour nutrition education intervention delivered virtually over a six month period
Study NCT05963971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Nutrition education per institutional standard of care
Study NCT05243589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: Proprioceptive training included exercises on different floor textures composed of 10 stations of exercises with the objective of stimulating the sole of the foot where participants had to coordinate gait by stepping with alternate feet on markers placed on the ground and the progression was manipulated through modifications of speed and direction.~Sequence of materials was 10 cm-thick foam, wood box with beans, two-cm thick mat with a density lower than the foam, wood box with cotton, two-cm thick mat volunteers sat on a bench and trained feet flexors by grasping with the toes a towel put on the floor, Two proprioception balls was used with an eight cm diameter with external projections resting on the floor a box with grains and sandpaper. After that joint Positional Sense Exercises were performed.
Study NCT05243589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine physical therapy
Description: Routine physical therapy included range of motion exercises for bilateral ankle joints (5 min.), functional balance training (15 min.) involving sit to stand (5 times); standing weight shift (5 times each); functional reach- sideway and anterior for touching targets set by the therapist (5 times each); bipedal heel rise for 20 seconds (5 times); unipedal standing for 15 seconds (5 times each) and unipedal standing with knee bending for 15 second (5 times each). Other exercises was practiced as wobble board training (6 min).
Study NCT05243589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine physical therapy
Description: Routine physical therapy included range of motion exercises for bilateral ankle joints (5 min.), functional balance training (15 min.) involving sit to stand (5 times); standing weight shift (5 times each); functional reach- sideway and anterior for touching targets set by the therapist (5 times each); bipedal heel rise for 20 seconds (5 times); unipedal standing for 15 seconds (5 times each) and unipedal standing with knee bending for 15 second (5 times each). Other exercises was practiced as wobble board training (6 min).
Study NCT06547073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise training
Description: Beat saber
Study NCT06547073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality exercise training
Description: Beat saber
Study NCT06547073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise training
Description: Bench slides, supine active assisted flexion, pendulum exercise, seated active assisted external rotation
Study NCT06113640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast and other CysLT1 antagonists are currently used as an adjuvant therapy for children and adults suffering from asthma. Other indications have been proposed and most evidence exists for the use of montelukast to treat allergic rhinitis, but its use in other inflammatory conditions, such as atherosclerosis and chronic obstructive pulmonary disease, have also been suggested.
Study NCT05423847 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: POCUS
Description: POCUS of lungs, pericardium and abdomen
Study NCT05032339 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IUO Plasma Cell Disorders Panel
Description: This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of plasma cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, plasma cell disorders.
Study NCT05222386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parkinson Disease Standard Care
Description: Under usual care, community providers will deliver their usual care and center coordinators will collect data on our outcomes every 3 months. After one year of baseline data collection, eight practices will be randomized to the intervention, which will include clinician training and coaching as well as access to online services for their patients. Per the stepped-wedge design an additional eight practices will be randomized 18 months into the data collection period, and the final eight will enter the intervention 24 months into the data collection period to allow for 12 months intervention recruitment for all practices.
Study NCT05512299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Magnetic Stimulation
Description: The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
Study NCT05222386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Online Community-Supported Palliative Care
Description: Neurologist Teleconferences: Training and coaching in palliative care will be provided using the Extension for Community Healthcare Outcomes (ECHO) model augmented by a Community of Inquiry Framework to address a desire for greater peer connection, enhance self-efficacy, and to address potential weaknesses in the ECHO model for more complex interventions such as palliative care.~Additional support services provided to carepartners and patients will be through the Family Caregiver Alliance's CareNav platform, including tailored educational materials, support groups and social support.
Study NCT04898673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1110
Description: Sound Processor
Study NCT04898673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1000
Description: Sound Processor
Study NCT05584072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Active pedal plantarflexion (APP) test
Description: Active pedal plantarflexion (APP) test
Study NCT05772013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Pill
Description: Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September).
Study NCT05772013 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin Pill
Description: Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September).
Study NCT05772013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
Study NCT05772013 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
Study NCT05385250 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bone sparring radiotherapy
Description: Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
Study NCT05078853 — intervention group
Intervention type: DEVICE
Intervention: Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node
Description: FNA Clinic: When a bloody material is seen in the needle, 100 µL of 0.9% saline is drawn via the needle into the syringe. The aspirate is then transferred into an Eppendorf tube. 40 µL is aspirated from the Eppendorf tube and dripped into the middle of the sample well of the POC-Tg kit. Two drops of the buffer are then dispensed into the middle of the sample well. The result of the POC-Tg is obtained and documented after 10 minutes. To compare the accuracy of the POC-Tg kit to the formal immunoassay for Tg, 0.9% saline is added to the aspirate that was left in the Eppendorf tube to a final volume of 0.6 mL. This volume is transferred into a gel containing tube and sent to the clinical laboratory that performs Tg measurement.~Operating room: When an indeterminate or suspicious LN is found, the LN is dissected and evaluated by both the formal evaluation and the POC-Tg. Following dissection of the LN, the ex-vivo POC-Tg is conducted as described above.
Study NCT06419023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supervised physical activity intervention using the Pilates Method (exercises on the mat)
Description: Each Pilates session was consisted of: a) introduction to the goal of training, familiarizing new skills (2-3 min); b) Pre-Pilates warm-up and respiratory exercises (5-10 min); c) mat Pilates exercises with the traditional Pilates repertoire: basic, beginner (40 min); d) cool down and endings exercises (5 min); e) session summary (2-3min). When required, exercises were adapted for breast cancer body needs and restrictions. Depending on the purpose of the exercise, different equipment was used (Pilates small ball 22 cm, Swiss ball, small massage balls, resistance band, towels, rollers, boxes, Magic Circle).
Study NCT06220708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dance movement therapy
Description: Our DMT program was adapted from an integrated somatic dance and visual arts program previously applied to the older population (Hsu, 2023). The intervention was scheduled in the afternoon and lasted for approximately 2 h. As previously recommended, rhythmic and contralateral movements on both sides of the body were emphasized in this study to enhance coordination and stimulation between the left and right cerebral hemispheres (Phillips-Silver and Trainor, 2007). The experimental groups were then subdivided into six groups. Balloons half-filled with water were used as the game in this study to guide individual and grouping rhythms and movements. Additionally, painting was incorporated to help participants understand their bodies and psychological states (Tjasink et al., 2023). Finally, group discussions and mutual support, along with verbal sharing after the DMT exercise, were encouraged.
Study NCT06220708 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: yoga training
Description: The yoga program included breathing exercises, Asanas, eye focus, body lock, and meditation. Participants were instructed to adjust their positioning based on their skill level to mitigate the risk of injury. The yoga intervention was scheduled at 2 pm and lasted for approximately 2 h.
Study NCT05792228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-led standardized intervention
Description: Once the patient in the intervention group decided to undergo cisplatin-based chemotherapy, the nurses would assess the risk factors associated with chemotherapy-induced nausea and vomiting (CINV) and reported to the physicians. During the chemotherapy, nurses would provide education on prevention and control of CINV using web-based approaches. All patients received standard antiemetic regimen, which included Aprepitant, 5-Hydroxytryptamine3-receptor antagonists, and Dexamethasone. If the physician's prescription was not accordance with the standard antiemetic regimen, nurse would remind the physician to adjust the prescription. Patients were recommended to eat small and frequent meals slowly. Overly spicy, fatty, and sweet foods should be avoided. Music relaxation therapy was performed for 60 min each time, once a day, and 3 times in the whole chemotherapy cycle. Follow-up was delivered until the 5th day after chemotherapy.
Study NCT05450471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid Topical
Description: The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.
Study NCT05450471 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04853342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Furmonertinib 80 mg
Description: The initial dose of Furmonertinib 80 mg once daily
Study NCT04853342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Furmonertinib 80 mg placebo
Description: The initial dose of Furmonertinib 80 mg once daily
Study NCT06427018 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: Observational study with no intervention.
Study NCT01037387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Current treatment according to the ATS/ERS guidelines
Study NCT01037387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIMV group
Description: Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
Study NCT04680689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 128 Multislice CT coronary angiography
Description: 128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium
Study NCT04680689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Cardiac Transthoracic Echocardiography
Description: 2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions
Study NCT04680689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Blood tests
Description: Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry
Study NCT06233487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Repeat hip ultrasound measurements
Description: See earlier
Study NCT05719805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days
Study NCT05294250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8
Description: XC8 10 mg film-coated tablets, 3 discrete doses of 20 mg each separated by 7-day wash-out periods